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Abstract
The development of forward genetic screens in human haploid cells has the potential to transform our understanding
of the genetic basis of cellular processes unique to man. So far, this approach has been limited mostly to the
identification of genes that mediate cell death in response to a lethal agent, likely due to the ease with which this
phenotype can be observed. Here, we perform the first reporter screen in the near-haploid KBM7 cell line to identify
constitutive inhibitors of NF-κB. CYLD was the only currently known negative regulator of NF-κB to be identified, thus
uniquely distinguishing this gene. Also identified were three genes with no previous known connection to NF-κB. Our
results demonstrate that reporter screens in haploid human cells can be applied to investigate the many complex
signaling pathways that converge upon transcription factors.
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Introduction
Forward genetic screens are a powerful means to decipher a
biological process without any prior knowledge or assumptions.
Typically such screens are performed in yeast, Drosophila,
Caenorhabditis elegans and other genetic model organisms to
identify new gene functions. Application of this method to
human cultured cells allows the dissection of pathways that are
dissimilar or even absent in other model organisms. It may also
enable the discovery of novel drug targets to treat disease.
Genetic screens in human cells have been limited by the
difficulties inherent in revealing recessive phenotypes in diploid
cells. While RNAi screens have been an important advance,
they are complicated by off-target effects and often do not
completely eliminate the relevant gene product. The recent
isolation of human cells lines that are nearly or completely
haploid (KBM7 and HAP1, respectively) has revolutionized
human forward genetic screens and led to the identification of
numerous human host factors required for infection by
pathogens and intoxication by bacterial toxins [1–7].
The majority of human haploid screens reported to date have
involved the selection of mutants that are resistant to an agent
that is lethal to wild-type cells. The one exception is a recent
screen that used fluorescence activated-cell sorting (FACS) to
identify genes involved in MHC (major histocompatibility
complex) class I antigen presentation by sorting for mutants
that were defective in surface expression of MHC-1 [8]. We
sought to further expand the types of biological pathways that
can be studied using human haploid genetic screens by using
a transcriptional reporter in conjunction with selection for a
lethal phenotype.
Transcription factors often lie at the terminus of complex
signaling pathways and control gene transcription programs
that regulate diverse processes, ranging from proliferation,
differentiation, apoptosis, immune response, to metabolism.
Given the importance of transcription factors in facilitating vital
aspects of cell biology, mutations in -or aberrant regulation of-
transcription factors have been associated with human disease
[9,10]. The identification of inhibitors or activators of
transcription factors will therefore not only illuminate the
signaling pathways that regulate them, but could also identify
targets that may prove to be better drug targets than
transcription factors themselves, or whose inhibition may
provide a more selective therapeutic effect.
We chose to screen for inhibitors of NF-κB, a family of
transcription factors that in mammals plays a central role in
regulating immune responses, development, cell proliferation,
and survival [11]. The NF-κB family consists of five members:
RelA/p65, RelB, c-Rel, NF-κB1 (p50 and its precursor p105)
and NF-κB2 (p52 and its precursor p100). They form dimers
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and are normally kept inactive in the cytoplasm. Activation of a
wide variety of receptors, including antigen receptors, pattern-
recognition receptors and cytokine receptors leads to
translocation of NF-κB dimers into the nucleus. Here the
dimers bind to DNA κB sites in promoters and enhancers of
target genes. Activation of NF-κB needs to be tightly controlled
and rapidly curtailed following the initial stimulus to prevent
uncontrolled tissue damage and/or disease.
Here we performed the first reporter screen in KBM7 cells to
identify constitutive inhibitors of NF-κB. The identification of
CYLD, a known negative regulator of NF-κB, demonstrates the
utility of using human haploid cells to dissect a variety of
biological processes.
Results
All screens in human haploid cells performed to date have
relied on intrinsic phenotypes, such as sensitivity to toxins or
protein surface expression, both of which can be easily
observed at a cellular level. To provide a clear phenotypic
readout for abrogation of NF-κB inhibitor function -and thus
improper activation of NF-κB-we generated a NF-κB reporter
cell line (Figure 1). We transduced KBM7 cells, which are
haploid for all chromosomes but chromosome 8, with a reporter
construct that contains a NF-κB transcriptional response
element (TRE) and a minimum cytomegalovirus (mCMV)
promoter upstream of the blasticidin S resistance gene (BSR)
from Bacillus cereus. Thus, insertional inactivation of genes
that normally repress activation of NF-κB would render the
reporter cells resistant to blasticidin and provide an easy
means to distinguish them from wild-type cells. To ensure that
the selected clonal reporter cell line had intact NF-κB
regulation, we stimulated both KBM7 cells and the NF-κB
reporter cell line with TNF (Figure 2). We saw that both cells
displayed similar IκBα degradation kinetics. The selected clonal
reporter cell line survived in the presence of blasticidin only
when stimulated with NF-κB activators, demonstrating that the
reporter functioned properly (Figure 3A). The NF-κB reporter
cell line was then mutagenized with a retroviral gene-trap
vector, using an established protocol that generally yields a
library containing mutations in approximately 98% of genes
expressed in KBM7 cells [1]. Mutagenized NF-κB reporter cells
were exposed to blasticidin and the survivors were pooled and
expanded. The selected mutant population was markedly more
resistant to blasticidin than the parental reporter cell line and
wild-type KBM7 cells in the absence of any stimulus,
suggesting that the survivors contain mutations that cause
constitutive activation of NF-κB (Figure 3B). To identify the
mutations in the selected mutant population, genomic DNA was
harvested from the survivors. The DNA sequences that flank
gene-trap insertion sites were amplified, sequenced in parallel,
and mapped to the human genome. We identified four genes
significantly enriched (p-value < 0.01) for disruptive mutations
in our blasticidin-selected population, as compared to a control
population of unselected mutagenized cells (Figure 4). In the
blasticidin-resistant population, CYLD, HEATR7A, LRRC8A,
and LRRC8D were represented with 4, 8, 3, and 26
independent inactivating gene-trap insertions (sense
orientation or present in an exon), respectively (respective p-
values of 6.91 x 10-5, 1.09 x 10-12, 7.88 x 10-4, and 9.71 x 10-37)
(Figures 4 and 5).
CYLD encodes a deubiquitylase (DUB) that targets NF-κB
signaling factors and is known to negatively regulate NF-κB
activation [12–14]. CYLD is expressed and active at steady-
state and it is thought to be constitutively required to prevent
spontaneous ubiquitylation of its targets and inappropriate
Figure 1.  NF-κB reporter haploid genetic screen.  KBM7
cells were transduced with a reporter containing a NF-κB
transcriptional response element (TRE) and a minimum CMV
(mCMV) promoter upstream of the blasticidin S resistance
gene (BSR) from Bacillus cereus. A clonal reporter cell line was
mutagenized by infection with a gene-trap virus. The resulting
cells were treated with blasticidin. Survivors were expanded
and DNA was extracted. DNA sequences flanking gene-trap
insertion sites were amplified and sequenced in parallel.
doi: 10.1371/journal.pone.0070339.g001
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activation of NF-κB in the absence of stimulus [15]. To confirm
that CYLD is constitutively required for proper regulation of NF-
κB in KBM7 cells, we employed shRNA-mediated knockdown
of CYLD in NF-κB reporter cells (Figure 6A). In the absence of
any stimulus, steady-state IκBα levels are lower in CYLD-
depleted cells as compared to cells expressing a control hairpin
against luciferase (Figure 6B). Upon TNF stimulation, IκBα
expression is lost more rapidly in CYLD-depleted cells. The
ability of our screen to specifically identify CYLD, but not other
established NF-κB inhibitors that are not required in the
absence of stimulus, validates the use of haploid reporter
screens to identify particular components of signaling
pathways.
HEATR7A is predicted to encode a protein of 1,641 amino
acids and has no known function. It contains seven HEAT
(Huntington, elongation Factor 3, protein phosphatase 2A,
TOR1) domains, a protein fold found in a variety of proteins
including the four that its name derives from. HEATR7A is
located on chromosome 8, the only chromosome to be present
in two copies in KBM7 cells suggesting that the mutations
caused by the gene trap insertions in HEATR7A are of a
dominant nature.
LRRC8A and LRRC8D represent two of five members of the
leucine-rich repeat-containing 8 (LRRC8) family of proteins that
are composed of four transmembrane domains at the N-
terminus, followed by up to 17 leucine-rich repeats [16]. Their
function is poorly understood, but LRRC8A and LRRC8C have
been implicated in B cell development and adipocyte
differentiation, respectively [17–19]. Thus it is not inconceivable
that there may exist a link between LRRC8s and NF-κB, given
the established function of NF-κB in lymphocyte differentiation
and its emerging role in metabolic disorders [11,20,21]. Given
that LRRC8D was identified with high confidence in our screen,
we sought to examine its function by isolating two clones that
carry gene trap insertions in the LRRC8D gene. While the
LRRC8D mutant cell lines were notably resistant to blasticidin,
examination by immunoblotting revealed no obvious impact of
LRRC8D deficiency on IκBα and p100 degradation (data not
shown). Our attempts to demonstrate a possible effect of the
LRRC8D disruptions on blasticidin import as an explanation for
the observed level of resistance were inconclusive, as the
fluorescently labeled or biotinylated versions of blasticidin we
prepared were themselves inactive on KBM7 cells. Thus we
can neither exclude the possibility that resistance is conferred
by differences in intracellular blasticidin levels, nor discount the
Figure 2.  NF-κB activity is regulated in KBM7 cells.  KBM7
and NF-κB reporter cells were stimulated with 10 ng/mL TNF
for the times indicated. Lysates were analyzed by immunoblot
with anti-IκBα. After stripping, the membrane was reprobed
with anti-actin antibodies to provide a loading control. Data are
representative of two independent experiments.
doi: 10.1371/journal.pone.0070339.g002
possibility of alternative modes of NF-κB activation not
accounted for by degradation of IκBα and p100 [22].
Discussion
Most genetic screens performed in human haploid cells have
sought to identify components in pathways required for cell
death in response to a lethal insult. Here we have
demonstrated that KBM7 cells can be modified with genetically
encoded transcriptional reporters to study more diverse cellular
processes. While we chose to screen for regulators -
specifically, inhibitors-of NF-κB, our method could presumably
be applied to study the approximately 1,391 human sequence
specific DNA binding transcription factors, many of whose
binding site profiles have recently been described [9,23].
By using resistance to blasticidin as our reporter read-out,
we were able to perform a selection -a genetic screen where
only mutants of interest survive-to identify mutants that
constitutively turned on the reporter. In principle, one could
perform a screen in a reversed fashion, in which only mutants
that fail to turn on the reporter survive, for example by
exploiting thymidine kinase or some other protein whose
expression could induce cell death. Identification of positive
regulators of transcription factors should thus be possible.
Fluorescent reporters could likewise be used in screens for
both positive and negative transcriptional regulators. Since
stringency in this type of screen would be more adjustable than
in a lethal screen, mutations that result in intermediate
phenotypes might be more easily recovered.
While the identification of CYLD validated our approach, we
were unable to identify mutations in other known negative
regulators of NF-κB. Perhaps the selection we performed was
particularly stringent. Presumably, only mutations that resulted
in constitutive activation of NF-κB could be recovered. Thus,
inhibitors whose function or expression is induced by NF-κB in
a negative feedback loop, such as A20 and Cezanne, may not
meet that criterion. In addition, loss-of-function mutations in
dominant-negative adaptors such as MyD88s, IRAK-M, and
SARM would not result in constitutive activation of NF-κB. We
did not recover mutations in IκBs, possibly because there is
some redundancy in function in KBM7 cells and removal of just
one IκB is not sufficient for constitutive activation of NF-κB. In
contrast, CYLD qualifies as a constitutively active inhibitor that
prevents spontaneous ubiquitylation of its targets [15]. CYLD
mutations are associated with constitutive activation of NF-κB
in multiple myeloma cells and B cells from mice deficient for
wild-type CYLD exhibited constitutive activation of NF-κB
[15,24,25].
Our haploid reporter screen confirms the absolute
requirement of CYLD function for proper regulation of NF-κB
and further supports constitutive NF-κB activity as the
mechanism underlying the development of human diseases
associated with CYLD mutations. Our screen identified genes
not previously known to be involved with NF-κB regulation.
Their exact role remains to be determined. The ability to
perform haploid reporter screens in human cultured cells opens
up many new cellular processes for investigation.
NF-κB Reporter Human Haploid Screen
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Materials and Methods
Plasmids
The NF-κB reporter was created by digesting pTRH1-NF-κB-
dscGFP (System Biosciences) with SpeI and SalI to remove
the dscGFP. The same restriction sites were used to insert a
synthesized DNA fragment encoding mCMV-NheI-Kozak
sequence-BamHI-Bacillus cereus BSR-Thosea asigna virus 2A
sequence-XbaI-Rabbit CYP4B1. Lentiviral shRNAs were
obtained from The RNAi Consortium (TRC) collection of the
Broad Institute. The TRC numbers for the shRNAs used are
TRCN0000072245 (shLuc) and TRCN0000039632 (shCYLD).
Cells
KBM7 cells were grown in Iscove’s modified Dulbecco’s
medium (IMDM) with 10% heat-inactivated fetal serum (IFS)
[3,26]. A NF-κB reporter cell line was created by transducing
KBM7 cells with the NF-κB reporter construct described above
Figure 3.  Demonstration of NF-κB reporter function.  A. Wild-type KBM7 and the clonal NF-κB reporter cell line were treated
with varying concentrations of blasticidin in the absence or presence of NF-κB activators (TNF, FSL-1). B. Wild-type KBM7, the
clonal NF-κB reporter cell line, and the polyclonal screen survivor population were treated with varying concentrations of blasticidin.
Cell viability was determined after 24 hours of treatment using the CellTiter Glo assay and results are plotted as percent viability of
treated cells compared with untreated cells. Results are mean ± SEM of triplicates and are representative of 3 independent
experiments.
doi: 10.1371/journal.pone.0070339.g003
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and single cells were sorted into individual wells of 96 well
plates. A clone that remained haploid and that died in the
presence of blasticidin S (Invivogen), but survived in blasticidin
when stimulated with NF-κB agonists was selected for the
screen.
Reporter haploid genetic screen
The screening procedure has been described previously
[1–6]. Briefly, 100 million NF-κB reporter cells were infected
with gene-trap retrovirus to create a mutagenized library. 200
million mutagenized cells were then plated 100,000 cells/well in
96 well plates with half in 10 µg/mL blasticidin S (Invivogen)
and half in 15 µg/mL blasticidin S for 6 days. After 6 days, the
media above the cells was replaced with antibiotic-free IMDM.
Survivors were allowed to expand for about three additional
weeks before harvest. DNA was harvested from ~30 million
cells from each of the two blasticidin conditions.
Sequence analysis of gene-trap insertion sites
The mapping of the insertion sites was done as previously
described [1–6]. In short, DNA sequences flanking gene-trap
insertions sites were amplified using an inverse PCR protocol
followed by sequencing using the Genome Analyzer platform
(Illumina). The sequences were then aligned to the human
genome. The number of inactivating mutations (that is, sense
orientation or present in exon) per individual gene was counted
as well as the total number of inactivating insertions for all
genes. Enrichment of a gene in the screen was calculated by
comparing how often that gene was mutated in the screen
compared to how often the gene carries an insertion in the
Figure 4.  Haploid reporter screen for constitutive inhibitors of NF-κB identifies CYLD.  Genes with sequenced inactivating
mutations are depicted as circles, the size of which corresponds to the number of independent insertions. Genes are ranked on the
x-axis according to their chromosomal position and along the y-axis according to the significance of the enrichment of gene-trap
insertions in the indicated gene compared to an unselected control dataset. Genes with a p-value lower than 0.01 are labeled and
the number of independent inactivating mutations is indicated between brackets.
doi: 10.1371/journal.pone.0070339.g004
NF-κB Reporter Human Haploid Screen
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e70339
Figure 5.  Schematic diagram of inactivating gene-trap insertion sites.  The loci of CYLD (NM_015247.2), HEATR7A
(NM_032450.2), LRRC8A (NM_019594.3), and LRRC8D (NM_001134479.1) are depicted with unique inactivating gene-trap
insertion sites (sense orientation or present in an exon) shown in red. For regions where there were many unique insertion sites, the
areas are blown up to reveal all unique sites. Gray boxes denote the 5’ and 3’ untranslated regions, and black boxes denote coding
exons.
doi: 10.1371/journal.pone.0070339.g005
NF-κB Reporter Human Haploid Screen
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control data set. For each gene, a P-value (corrected for false
discovery rate) was calculated using the one-sided Fisher
exact test.
Immunoblot analysis of TNF stimulated cells
Two million cells were used per condition. Cells were
washed once in ice-cold PBS and then lysed in buffer
containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5 mM
EDTA, protease inhibitors (Roche) and 1% (v/v) NP40. Protein
concentrations of lysates were determined by Bio-Rad Protein
Assay and then normalized across samples. Proteins from total
lysates were resolved by 10% SDS-PAGE and analyzed by
immunoblotting with primary antibodies: mouse anti-IκBα (BD
#610690) at 1:500 dilution and mouse anti-actin (BD #612656)
at 1:10,000. Horseradish peroxidase (HRP)-conjugated sheep
anti-mouse IgG (GE NXA931) was used at 1:5,000 dilution.
Restore PLUS Western Blot Stripping Buffer (Thermo) was
used to strip the membranes between probing for IκBα and
actin.
Cell viability assay
CellTiter-Glo Luminescent Cell Viability Assay (Promega)
was used to quantify cell viability. 200,000 cells were seeded
per well in Optilux clear-bottom 96-well plates (BD Falcon) in
IMDM or IMDM supplemented with varying concentrations of
Blasticidin S (Invivogen), TNF-α (Invivogen), FSL-1 (Invivogen)
for 24 hours before reading on a Luminoskan Ascent
luminometer (Thermo Scientific).
Quantitative real-time PCR
RNA was extracted using a RNAeasy kit (QIAGEN) followed
by on-column DNase I (QIAGEN) digestion. SuperScript III
First-Strand Synthesis System (Invitrogen) was used for the
reverse transcription reaction using Oligo dT primers. SYBR
Green PCR Master Mix (Applied Biosystems) was used
according to manufacturer’s instructions. Real-time PCR
reactions were run on an ABI 7900HT machine. PCR volume
was 20 µL (96-well plate), and data values were derived from
three replicates using the comparative Ct method. Primers
used for CYLD were 5’ GGTAATCCGTTGGATCGGTCAGC 3’
and 5’ TGCAAACCTAGAGTCAGGCCTGC 3’. Primers used
for GAPDH were 5’ ACCCACTCCTCCACCTTTGACG 3’ and 5’
CACCCTGTTGCTGTAGCCAAATTCG 3’.
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